クローン病における中等度の術後再発の管理: 治療エスカレーションのランダム化対照試験、POMEROL 試験。 (ポムロール) (POMEROL)
Study type : A 30 months, multicentre, open-label strategic randomized controlled trial
Population : Chron's Disease (CD) patients with an i2 endoscopic postoperative recurrence in the year following ileocolonic resection (6-12months after ileocolonic resection).
Treatments :
Stratification at inclusion according to prophylactic therapy.
Patients randomized in 2 arms:
- Status quo arm: if the patient received no prophylactic therapy, no treatment will be started; if the patient received a prophylactic therapy, the same will be continued at the same dose.
- Therapy escalation arm: infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.
Main objective : To evaluate the proportion of CD patients without endoscopic postoperative recurrence (i0-i1) at 12 months in the arm receiving therapy escalation compared to status quo arm in patients having an i2 endoscopic postoperative recurrence 6-12months after ileocolonic anastomosis with restoration of faecal stream.
調査の概要
詳細な説明
Number of patients : 360 patients in approximatively 25 sites in France.
Recruitement period : The trial duration for each patients will be 12 months from radomization (18 to 24 months from screening (ie : post-operatively))
Endpoints:
Primary endpoints: Proportion of patients with an i0-i1 modified Rutgeerts score at 12 months.
Secondary endpoints:
-
Proportion of patients with an i3-i4 modified Rutgeerts score at 12 months
-
Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months
-
Proportion of patients with an i0 modified Rutgeerts score at 12 months
-
PRO2 score at 12 months
-
Clinical postoperative recurrence within 12 months: average daily SF ≥ 3.5 and average daily AP score ≥ 1.5, AND
- increased CRP compared to inclusion, at least + 10 mg/l
- OR increased fecal calprotectin compared to inclusion, at least + 250 μg/g
-
Surgical recurrence within 12 months: need for a new ileocolonic resection
-
Endoscopic dilatation within 12 months: need for a balloon insufflation at the ileocolonic anastomosis during an ileocolonoscopy when a non-passable stenosis was present in patient having obstructive symptoms (CDOS > 4) before endoscopy
-
Time to clinical postoperative recurrence
-
Serious adverse events
-
Quality of life: EQ5D-5L questionnaire
-
Work productivity: Work Productivity and Activity Impairment questionnaire
研究の種類
入学 (実際)
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
-
Paris、フランス、75009
- GETAID
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Crohn's disease diagnosed according usual criteria
- Bowel resection with ileocolonic anastomosis performed removing all inflammatory lesions
- Postoperative endoscopy performed between 6 and 12 months after ileocolonic anastomosis reaching the neoterminal ileum (patients who underwent a two stage surgical procedure are also eligible if the endoscopic evaluation is performed 6-12 months after restoration of the fecal stream)
- Moderate endoscopic postoperative recurrence classified i2 according to the Rutgeerts score at 6-12 months, validated by a blinded central reading
Exclusion Criteria:
- Patients with an ostomy
- Ulcerative colitis or IBD type unclassified
- Ileorectal or ileal pouch-anal anastomosis
- Symptoms defined as average daily SF ≥ 3.5 and average daily AP score ≥ 1.5 having started after a free interval without symptoms of at least one month after surgery
- Patients with obstructive symptoms of CD defined by a CDOS > 4
- Patients exposed to infliximab before index surgery with a primary non-response (no clinical effect after 2 infusions at the discretion of the treating gastroenterologist) or history of infusion reactions to infliximab or history of detectable anti-infliximab antibodies
- Patients treated with biological therapy (except for intraocular injections) or an investigational medical product after index surgery
- Patients having started thiopurines or methotrexate more than 6 weeks after ileocolonic anastomosis with restoration of the fecal stream
- Patients in whom not all inflammatory lesions have been removed at index surgery
- Patients with active perianal Crohn's disease
- Patients with a contraindication to infliximab: cancer in the 5 years prior to inclusion excluding non-melanoma skin cancer, active tuberculosis or untreated latent tuberculosis, moderate or severe heart failure, HIV or HBV infection (serology < 6 months), recent live vaccination (within 4 weeks of baseline)
- Pregnant women
- Patients under legal protection or unable to express their consent.
- Patients not affiliated to a health insurance system.
- Patients deprived of liberty by judiciary or administrative decision or hospitalized without consent or admitted in a sanitary or social institution for another reason than research.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:Status quo arm
If the patient received no prophylactic therapy after resection, no treatments will be started. If the patient received a prophylactic therapy after resection, the same will be continued at the same dose. |
Stratification 1 : No treatments Stratification 2 : Immunosuppressors at same dose |
|
実験的:Therapy escalation arm
Infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards. |
Stratification 1: Infliximab-CT-P13 Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of patients with an i0-i1 modified Rutgeerts score at 12 months.
時間枠:Month12
|
Number of patients with an i0-i1 modified Rutgeerts score at 12 months. |
Month12
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of patients with an i3-i4 modified Rutgeerts score at 12 months
時間枠:Month 12
|
Number of patients with an i3-i4 modified Rutgeerts score at 12 months |
Month 12
|
|
Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months
時間枠:Month 12
|
Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months |
Month 12
|
|
Proportion of patients with an i0 modified Rutgeerts score at 12 months
時間枠:Month 12
|
Proportion of patients with an i0 modified Rutgeerts score at 12 months |
Month 12
|
|
Patient Reporting Outcome score at 12 months.
時間枠:Screening, Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
Patient Reporting Outcome score at 12 months will be assessed for the evaluation of disease activity (clinical remission). |
Screening, Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
|
Clinical postoperative recurrence
時間枠:Baseline, Month 4, Month 8, Month 12
|
Clinical postoperative recurrence within 12 months defined by : Average daily Stool Frequency ≥ 3.5 and average daily Abdominal Pain score ≥ 1.5, AND
Average daily Stool frequency, average daily Abdominal Pain score, CRP and Calprotectin feacal will be combined to report the clinical postoperative recurrence (this outcome is is expressed without units) |
Baseline, Month 4, Month 8, Month 12
|
|
Surgical recurrence within 12 months
時間枠:Baseline, Month 4, Month 8, Month 12
|
Surgical recurrence within 12 months defined by need for a new ileocolonic resection. Proportion of surgical recurrence within 12 months |
Baseline, Month 4, Month 8, Month 12
|
|
Endoscopic dilatation within 12 months
時間枠:Baseline, Month 4, Month 8, Month 12
|
Endoscopic dilatation within 12 months defined by a need for a balloon insufflation at the ileocolonic anastomosis during an ileocolonoscopy when a non-passable stenosis was present in patient having obstructive symptoms (CDOS > 4) before endoscopy Proportion of endoscopic dilatation within 12 months |
Baseline, Month 4, Month 8, Month 12
|
|
Time to clinical postoperative recurrence will be assessed
時間枠:Baseline, Month 4, Month 8, Month 12
|
Time to clinical postoperative recurrence will be assessed |
Baseline, Month 4, Month 8, Month 12
|
|
Serious adverse events
時間枠:Screening, Baseline, Month 4, Month 8, Month 12
|
Occurence of Serious Adverse Events |
Screening, Baseline, Month 4, Month 8, Month 12
|
|
Quality of life: EQ5D-5L questionnaires
時間枠:Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
Quality of life will be assessed with the EQ5D-5L questionnaire |
Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
|
Work productivity and activity impairement questionnaires
時間枠:Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
Work productivity and activity impairement will be assessed with work productivity and activity impairement questionnaires |
Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- GT-2021-01
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。